Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells

<p dir="ltr">Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells. A-C) The significantly top-downregulated GO pathways in AD-MSCs (A), PSCs (B), and BM-MSCs (C) after treatment with the KC and KCM serum.</p>

Uloženo v:
Podrobná bibliografie
Hlavní autor: Sushil Kumar (20371917) (author)
Vydáno: 2025
Témata:
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
_version_ 1849927637244313600
author Sushil Kumar (20371917)
author_facet Sushil Kumar (20371917)
author_role author
dc.creator.none.fl_str_mv Sushil Kumar (20371917)
dc.date.none.fl_str_mv 2025-11-25T00:35:59Z
dc.identifier.none.fl_str_mv 10.6084/m9.figshare.27948372.v1
dc.relation.none.fl_str_mv https://figshare.com/articles/figure/Supplementary_Figure_5_Pathway_analysis_after_treatment_with_KC_and_KCM_serum_in_precursor_cells/27948372
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Cancer cell biology
pancreatic cancer
stroma
epigenetics
CAF heterogeniety
Muc5ac
dc.title.none.fl_str_mv Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells
dc.type.none.fl_str_mv Image
Figure
info:eu-repo/semantics/publishedVersion
image
description <p dir="ltr">Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells. A-C) The significantly top-downregulated GO pathways in AD-MSCs (A), PSCs (B), and BM-MSCs (C) after treatment with the KC and KCM serum.</p>
eu_rights_str_mv openAccess
id Manara_0ce7d594a339f3b328a34788a181ce7e
identifier_str_mv 10.6084/m9.figshare.27948372.v1
network_acronym_str Manara
network_name_str ManaraRepo
oai_identifier_str oai:figshare.com:article/27948372
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cellsSushil Kumar (20371917)Cancer cell biologypancreatic cancerstromaepigeneticsCAF heterogenietyMuc5ac<p dir="ltr">Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells. A-C) The significantly top-downregulated GO pathways in AD-MSCs (A), PSCs (B), and BM-MSCs (C) after treatment with the KC and KCM serum.</p>2025-11-25T00:35:59ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.6084/m9.figshare.27948372.v1https://figshare.com/articles/figure/Supplementary_Figure_5_Pathway_analysis_after_treatment_with_KC_and_KCM_serum_in_precursor_cells/27948372CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/279483722025-11-25T00:35:59Z
spellingShingle Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells
Sushil Kumar (20371917)
Cancer cell biology
pancreatic cancer
stroma
epigenetics
CAF heterogeniety
Muc5ac
status_str publishedVersion
title Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells
title_full Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells
title_fullStr Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells
title_full_unstemmed Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells
title_short Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells
title_sort Supplementary Figure 5: Pathway analysis after treatment with KC and KCM serum in precursor cells
topic Cancer cell biology
pancreatic cancer
stroma
epigenetics
CAF heterogeniety
Muc5ac